The annual Auditor General Report has become, after all, one of the most anticipated government publications. The increasing public interest, has not, Ambrin says, changed the way the National Audit Department operates but it has certainly impressed on him and his team the importance and seriousness of the task at hand. He has rather a tough and challenging job that requires a high degree of professionalism, independence and transparency. The year-old leads a 2,strong team responsible for auditing all public sector accounts and finances, encompassing the federal and state governments, state and federal statutory bodies, local authorities and even government-linked companies.
Co-administration of quinidine or dofetilide with Itraconazole may increase plasma concentrations of quinidine or dofetilide, which could result in serious cardiovascular events. Therefore, concomitant administration of Itraconazole and quinidine or dofetilide is contraindicated.
The Class IA antiarrhythmic, disopyramide has the potential to increase the QT interval at high plasma concentrations. Caution is advised when Itraconazole and disopyramide are administered concomitantly.
Concomitant administration of digoxin and Itraconazole has led to increased plasma concentrations of digoxin via inhibition of P-glycoprotein. Reduced plasma concentrations of Itraconazole were reported when Itraconazole was administered concomitantly with phenytoin.
Although interactions with carbamazepine and phenobarbital have not been studied, concomitant administration of Itraconazole and these drugs would be expected to result in decreased plasma concentrations of Itraconazole.
In addition, in vivo studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. Although there are no data regarding the effect of Itraconazole on carbamazepine metabolism, because of the similarities between ketoconazole and Itraconazole, concomitant administration of Itraconazole and carbamazepine may inhibit the metabolism of carbamazepine.
Human pharmacokinetic studies have shown that efavirenz, when concomitantly administered with Itraconazole, greatly decreased serum concentrations of Itraconazole and hydroxyl-itraconazole. Concomitant use of Itraconazole and efavirenz is not recommended.
In vivo studies have shown that nevirapine induces the metabolism of ketoconazole, significantly reducing the bioavailability of ketoconazole. Studies involving nevirapine and Itraconazole have not been conducted.
However, because of the similarities between ketoconazole and Itraconazole, concomitant administration of Itraconazole and nevirapine is not recommended. Concomitant administration of Itraconazole and protease inhibitors metabolized by CYP3A4, such as indinavir, ritonavir, and saquinavir, may increase plasma concentrations of these protease inhibitors.
In addition, concomitant administration of Itraconazole and indinavir and ritonavir but not saquinavir may increase plasma concentrations of Itraconazole. Caution is advised when Itraconazole and protease inhibitors must be given concomitantly.
Concomitant administration of Itraconazole and maraviroc has been reported to increase plasma concentration of maraviroc. The dose of maraviroc should be decreased to mg twice daily when given in combination with Itraconazole. Antimycobacterials Drug interaction studies have demonstrated that plasma concentrations of azole antifungal agents and their metabolites, including Itraconazole and hydroxyitraconazole, were significantly decreased when these agents were given concomitantly with rifabutin or rifampin.
In vivo data suggest that rifabutin is metabolized in part by CYP3A4. Itraconazole may inhibit the metabolism of rifabutin. Although no formal study data are available for isoniazid, similar effects should be anticipated.
Therefore, the efficacy of Itraconazole could be substantially reduced if given concomitantly with one of these agents and co-administration is not recommended.
Antineoplastics Itraconazole may inhibit the metabolism of busulfan, docetaxel, and vinca alkaloids. Co-administration of pimozide with Itraconazole could result in serious cardiovascular events. Therefore, concomitant administration of Itraconazole and pimozide is contraindicated.
Increases in plasma aripiprazole concentrations have been demonstrated in subjects concomitantly receiving ketoconazole, requiring a reduction of the aripiprazole dose. Because of the similarities between ketoconazole and Itraconazole, a similar dose reduction for aripiprazole is recommended when patients concomitantly receive Itraconazole and aripiprazole.
Benzodiazepines Concomitant administration of Itraconazole and alprazolam, diazepam, oral midazolam, or triazolam could lead to increased plasma concentrations of these benzodiazepines. Increased plasma concentrations could potentiate and prolong hypnotic and sedative effects.
Concomitant administration of Itraconazole and oral midazolam or triazolam is contraindicated. If midazolam is administered parenterally, special precaution and patient monitoring is required since the sedative effect may be prolonged.
Calcium Channel Blockers Calcium channel blockers can have a negative inotropic effect which may be additive to those of Itraconazole; Itraconazole can inhibit the metabolism of calcium channel blockers such as dihydropyridines e.
Therefore, caution should be used when co-administering Itraconazole and calcium channel blockers due to an increased risk of CHF. Concomitant administration of Itraconazole and nisoldipine results in clinically significant increases in nisoldipine plasma concentrations, which cannot be managed by dosage reduction, therefore the concomitant administration of Itraconazole and nisoldipine is contraindicated.
A clinical study showed that felodipine exposure was increased by co-administration of Itraconazole, resulting in approximately 6-fold increase in the AUC and 8-fold increase in the Cmax.
The concomitant use of Itraconazole and felodipine is contraindicated. Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.John Hancock Funds II - ‘N-Q’ for 11/30/16 - Quarterly Schedule of Portfolio Holdings of a Management Investment Company - Seq.
1 - Accession Number - Filing - SEC. This is the first web site to compute fair values for common stock. This is the most comprehensive web site using more than 25 quantitative models to derive fair values for over 50, stocks and ETF’s across 30 countries on a daily basis.
Additionally, we publish daily portfolios of mispriced stocks and track various proprietary indexes for mispricing. Hovid Bhd is engaged in the manufacture of pharmaceutical and herbal products.
The firm operates through the Manufacture and Sale of Pharmaceutical Products segment. The company offers products, such as Ethical Drugs, Dietary Supplements, Consumer Products, . • Hovid’s GPM higher than Pharmaniaga’s due to: • Premium pricing of Hovid’s products • Manufacturing its own products as compared to Pharmaniaga (which outsourced its .
You just clipped your first slide! Clipping is a handy way to collect important slides you want to go back to later. Now customize the name of a clipboard to store your clips.
Jalan timberdesignmag.com Sdn. Level 2. NSDK. Batu NILAI. PNB Darby Park No. Jalan Kuala Kangsar Ipoh Perak How Yow Turnparts Industrial Sdn Bhd Lot Telekom Malaysia Berhad Aras 10 Selatan. NSDK HUME FIBREBOARD SND BHD LOT Block B.
HUACOMM TELECOMMUNICATIONS HOTEL ISTANA KL.